CD8 + T cells play a central role in antitumour immunity, which often exhibit 'exhaustion' in the setting of malignancy and chronic viral infection due to T cell immunoglobulin and mucin domain 3 (TIM3) and myeloid-derived suppressor cells (MDSCs).
| INTRODUC TI ON
Myelodysplastic syndromes (MDS) are malignant bone marrow disorders characterized by ineffective haematopoiesis and high risk to transformation into acute myeloid leukaemia. Increased malignant clones and cellular immunodeficiency might contribute to the pathogenesis of MDS. 1-5 Cytotoxic T lymphocytes (CTLs) play a central role in tumour immunity. 6 Adoptive T cell immunotherapy in neoplastic disorders has been restricted by CD8 + T cells 'exhaustion' due to some immune checkpoint inhibitors, such as T cell immunoglobulin and mucin domain 3 (TIM3), programmed death-1 (PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4) and lymphocyte-activation gene 3 (LAG3). 7, 8 Among these immune checkpoints, the interaction of TIM3 with its ligand galectin-9 (Gal-9) promotes Tc1 cells 9 apoptosis, CD8 + T cells exhaustion, 10, 11 malignant cell proliferation 12 and myeloid-derived suppressor cells (MDSCs) amplification. 13 In humans, MDSCs are usually defined as CD14 − CD11b + cells or the cells which express the myeloid marker (CD33) and are lack of lineage maturation markers and HLA-DR 14 (Lin − HLA-DR − CD33 + cells). In previous research, increased Lin − HLA-DR − CD33 + MDSCs in MDS patients were observed, and this cell population was obviously separated by flow cytometry than other labelled cells. We also found that CD8 + T cells could be inhibited by MDSCs, which were 'crazy' in MDS patients. CD8 + T cells with less INF-γ overexpressed TIM3 in MDS patients. Further, TIM3 + CD8 + T cells produce less perforin and granzyme B. 1, 2 The hypothesis that CD8 + T cells exhaustion might be induced by MDSCs through TIM3/Gal-9 pathway drove us to detect Gal-9 expression in MDSCs, and the level of perforin and granzyme B in CD8 + T cells after co-culture with MDSCs or excess exogenous Gal-9 or TIM3/Gal-9 pathway inhibitors. We also explored Notch1, eomesodermin (EOMES), phospho-mTOR (p-mTOR) and phospho-AKT (p-AKT) proteins, which are related to the function and proliferation of CD8 + T cells, 15, 16 to verify that TIM3/Gal-9 pathway might be involved in CD8 + T cells exhaustion induced by MDSCs in MDS patients.
| MATERIAL S AND ME THODS

| Patients
Fifty-two treatment-naive Chinese MDS patients (32 males and 20 females, median age 64, Table 1 ) who were newly diagnosed according to the WHO classification 17 Thirty-one healthy volunteers (mean age 44.48 ± 14.87) were enrolled. There was no difference in the sex ratio or age between MDS patients and normal healthy volunteers (P > .05).
The study was approved by the Ethics Committee of Tianjin Medical University General Hospital. Informed written consents were obtained from all the patients and normal controls following the Declaration of Helsinki.
| Flow cytometry analysis
| Membrane markers and intracellular markers detection
One hundred microlitres of peripheral blood and bone marrow samples from MDS patients and healthy volunteers were placed in heparin-containing anticoagulant tubes. The specimens were incubated with 15 µL of Lin/HLA-DR/CD33 and their isotype control antibodies at 4°C for 30 minutes. After incubation, erythrocytes were lysed with 2 mL of erythrolysin for 10 minutes, centrifuged at 400 g for 5 minutes and washed twice with phosphate buffered saline (PBS). After permeabilizing the cell membrane using an IntraSure Kit (BD Biosciences), 5 μL galectin-9 monoclonal antibody was added to the cells, incubated for 20 minutes at 4°C in the dark and washed twice with PBS. Finally, 5 × 10 5 cells per tube were detected by flow cytometry. After CD8 + T cells and MDSCs were co-cultured, they were co-incubated with CD3/CD8 antibodies in the same way. For intracellular staining, the samples were incubated with perforin and granzyme B antibodies after permeabilizing the cell membrane. The phenotype of MDSCs was analysed for the cell surface markers Lin, HLA-DR and CD33. Intracellular expression of galectin-9 was determined. Perforin or granzyme B expression in co-cultured CD8 + T cells was analysed. All data were collected on a flow cytometer (Beckman Coulter), and the results were analysed with Kaluza software (Beckman Coulter).
The labelled antibodies included CD3-APC (SK7, BD Biosciences), CD3-PE (SK7, BD Biosciences), CD8-FITC (SK1, BD Biosciences), TIM3-APC (7D3, BD Biosciences), Lin-FITC (BD Biosciences), HLA-DR-PerCP (L243, BD Biosciences), CD33-APC (WM53, BD Biosciences), galectin-9-PE (9M1-3, BD Biosciences), perforin-PE (δG9, BD Biosciences) and granzyme B-PE (GB11, BD Biosciences).
The above antibodies were added as described by the manufacturer.
| Detection of apoptosis
An apoptosis assay (FITC Annexin V Apoptosis Detection Kit I, BD
Biosciences) was used to detect apoptosis of CD8 + T cells co-cultured with MDSCs. The cells were washed twice with cold PBS and were resuspended in 1× binding buffer at a concentration of 1 × 10 6 cells/ mL. Then, 100 µL of the solution (1 × 10 5 cells) was transferred to a 5-mL culture tube, and 5 µL of FITC Annexin V and 5 µL of PI were added. The cells were gently vortexed and incubated for 15 minutes at room temperature (25°C) in the dark. Finally, 400 µL of 1× binding buffer was added to each tube. Analysis was performed by flow cytometry (Beckman Coulter). 
TA B L E 1
| Sorting CD8 + T cells and MDSCs
Ten millilitres of fresh peripheral blood or bone marrow was obtained from MDS patients or normal controls (NC). Human CD8 + immunomagnetic bead solution (Miltenyi Biotec) (50 µL) was added to mononuclear cells, which were obtained by Ficoll gradient centrifugation. The samples were incubated for 15 minutes at 4°C and washed once with buffer, and the suspension cells were passed through the MS column in the magnetic field. Then, the column was removed from the magnet and 1 mL of wash buffer was added to the top of the column and the plunger (in the same package as the column) was immediately used to force the buffer through the column. The collected cells were used for the subsequent experiments.
Ten millilitres of bone marrow was obtained from MDS patients, and red blood cells were lysed with lysing solution (BD Biosciences) and washed with PBS; and then, 40 µL of Lin\HLA-DR\CD33 antibodies were added to label the surface markers of the MDSCs. The cells were co-incubated for 30 minutes at 4°C in the dark and washed with PBS. The cells were collected by the FACS Aria II (BD Biosciences).
| Cells culture
| Culture MDSCs
MDSCs were sorted by flow cytometry and then cultured with 10% foetal bovine serum (FBS) (containing 60 mg/L penicillin and 100 mg/L streptomycin) (Gibco) in the presence of 50 ng/mL recombinant human (rh) granulocyte-monocyte colony-stimulating factor (GM-CSF) (PeproTech Inc) at 37°C in a 5% CO 2 incubator. The culture supernatants were collected after 48 hours for ELISA.
| Co-culture of CD8 + T cells with MDSCs
To investigate whether MDSCs affect the function of CD8 + T cells via the TIM3/Gal-9 pathway, 10 5 CD8 + T cells and MDSCs (>95% Lin − HLA-DR − CD33 + cells) at a ratio of 1:2 were supplemented with 
| Co-culture of CD8 + T cells with exogenous Gal-9
CD8 + T cells selected by magnetic beads were co-cultured with 2 ng/mL exogenous recombinant human Gal-9 (R&D Systems) with 10% FBS (containing 60 mg/L penicillin and 100 mg/L streptomycin) at 37°C in a 5% CO 2 incubator for 24-48 hours. Then, the expression of perforin, granzyme B and pathway-related proteins in CD8 + T cells were detected with or without TIM3/Gal-9 inhibitors. 
| Proliferation assay
| Real-time PCR
| Enzyme-linked immunosorbent assay (ELISA)
Bone marrow supernatants, serum and culture supernatants of MDSCs from MDS patients and normal controls were harvested. The levels of Gal-9 were measured by using a Human Galectin-9 ELISA Kit (KAMIYA Biomedical Company) according to the manufacturer's instructions.
| Western blot analysis
CD8 + T cells cultured alone and co-cultured with exogenous Gal-9
were collected and lysed in RIPA buffer supplemented with complete protease inhibitors and phosphatase inhibitors (Roche 
| Statistical analysis
Prism statistical software (v7.00; GraphPad Software, Inc, La Jolla, CA, USA) was applied for data analysis. Statistical differences between two groups were analysed using Student's t test. One-way ANOVA was used to compare three groups or more. All data are presented as the mean ± standard error of the mean (normal distribution data) or median (25% percentile-75% percentile) (non-normal distribution data).
| RE SULTS
3.1 | Galectin-9 was highly expressed in MDSCs, and Gal-9 was also elevated in bone marrow supernatants, serum and culture supernatants of MDSCs from MDS patients compared to those from normal controls that MDSCs might release Gal-9 into the bone marrow microenvironment and exert immunosuppressive effects.
| Perforin, granzyme B and proliferation of CD8 + T cells in normal controls decreased after cocultivation with MDSCs, while the early apoptosis of CD8 + T cells increased
To demonstrate the inhibitory effects of MDSCs on immune cells, (Figure 2A Figure 2D ); there was an upward trend in co-cultured group as seen in the flow cytogram, although there was no significant difference( Figure 2E ).
| Perforin, granzyme B and early apoptosis of CD8 + T cells from MDS after co-cultivation with MDSCs
| Perforin and granzyme B decreased in CD8 + T cells from MDS patients after co-cultivation with MDSCs, which was partially restored by TIM3/Gal-9 pathway inhibitors
We hypothesized that MDSCs might suppress CD8 + T cells through TIM3/Gal-9 signalling pathway. Therefore, we purified CD8 + T cells from MDS patients and co-cultured them with MDSCs, F38-2E2 (TIM3 inhibitor) and 9M1-3 (Gal-9 inhibitor) respectively. When the concentration of inhibitor was 10 µg/mL, an obvious effect was observed ( Figure 3D ). .79%), P < .0001****) ( Figure 3A-C) . The inhibitors had no effect on CD8 + T cells cultured alone ( Figure 3E ).
| The early apoptosis of CD8 + T cells increased after co-cultivation with MDSCs and was partially restored by blocking the TIM3/Gal-9 pathway
We detected early apoptosis of CD8 + T cells from 11 MDS patients (numbers: 003-005, 027-031 and 038-040) after co-culture with MDSCs and found that early (Annexin V + PI − ) apoptosis was higher than that of CD8 + T cells alone. Furthermore, early apoptosis was reduced after co-culture with the TIM3 inhibitor (F38-2E2) and 17.15 ± 4.66%, P = .0002***) ( Figure 4A,B ).
| Decreased perforin and granzyme B in CD8 + T cells after co-cultivation with excess exogenous Gal-9
We speculated that MDSCs might be a source of Gal-9 due to its overexpression; therefore, we took excess exogenous Gal-9 in the place of MDSCs and co-cultured CD8 + T cells with excess exogenous Gal-9 (recombinant human Gal-9 [R&D Systems]) and TIM3/Gal-9 pathway inhibitors.
The perforin and granzyme B in CD8 + T cells purified from MDS patients (n = 9, samples: 026-028, 034, 036, 037 and 045-047) were significantly lower after co-cultivation with excess exogenous Gal-9
than those in CD8 + T cells alone and were partially restored by TIM3 inhibitor or Gal-9 inhibitor (perforin%: i: 15.33 ± 2.83% vs a:
21.79 ± 3.35% vs j: 20.63 ± 3.37% vs k: 19.01 ± 3.49%, P < .0001****;
granzyme B%: i: 15.95 ± 5.47% vs a: 21.32 ± 6.56% vs j: 20.18 ± 6.44% vs k: 18.38 ± 6.07%, P = .0019**) ( Figure 5A -C).
| Notch1, EOMES, p-mTOR and p-AKT decreased in CD8 + T cells after co-cultivation with excess exogenous Gal-9
We further explored the mechanism of CD8 + T cell suppression by 34.81 ± 7.96% vs 26.37 ± 6.65%, P < .05*) ( Figure 6A ).
The mammalian target of rapamycin (mTOR) is a serine/threonine (Thr)-protein kinase that plays a key role in regulating cell growth and proliferation. The expression of p-mTOR and p-AKT in CD8 + T cells (n = 9, samples: 027-037, except 035,036) treated with excess exogenous Gal-9 was lower compared to those of CD8 + T cells alone (p-mTOR: 6.44 ± 2.30% vs 3.15 ± 0.88%, P < .01**; p-AKT:
25.57 ± 9.73% vs 15.78 ± 6.21%, P < .01**, Figure 6A ). A downward trend in Notch1, EOMES, p-mTOR and p-AKT was observed in CD8 + T cells after co-cultivation with excess exogenous Gal-9 by Western blotting ( Figure 6B ).
| D ISCUSS I ON
T cell exhaustion, a state of T cell dysfunction characterized by diminished cytokine production and elevated apoptosis, was first characterized in the settings of chronic lymphocytic choriomeningitis virus (LCMV) infection. 18 T cell exhaustion could also occur in viral infections such as hepatitis C virus and HIV 19, 20 as well as in tumour models 11, 21 and haematological malignant diseases. 22 The exhausted T cells highly express immune checkpoints, such as TIM3,
PD-1 and CTLA-4. 6, 23 Blocking TIM3 and PD-1 can reverse T cell exhaustion and dysfunction in malignant tumour patients 21, 24, 25 or neoplastic mice. 26 TIM3, as one of the important immunity checkpoints, interacts with its ligand Gal-9 24 could promote Tc1 cell 9 apoptosis, CD8 + T cell exhaustion, 10,11 malignant cell proliferation 12 and MDSC proliferation. 13 MDSCs, which are powerful cellular immunity suppressor, could badly inhibit the antitumour immune response mediated by the effector T cells and lead to tumour cells immunological surveillance escape. 28, 29 Here, we found that Gal-9 was also highly expressed in MDSCs were much lower than that in real infectious diseases. These suggested that cellular immunity was insufficient for malignant clonal cells due to cellular immunity tolerance, both in low-risk and highrisk MDS groups. We found that there was no difference of Gal-9
in MDSCs of high-risk and low-risk MDS patients, which was consistent with our hypothesis. Therefore, further exploration of the molecular mechanism of Gal-9 up-regulation is needed.
Perforin and granzyme B are the most important cytokines in CD8 + T cells against infectious and malignant cells. MDSCs can inhibit CD8 + T cells in esophageal squamous cell carcinoma. 8 Here, perforin, granzyme B and proliferation decreased and the early apoptosis of CD8 + T cells increased after CD8 + T cells from controls were co-cultured with MDSCs. These data implied that MDSCs with excessive Gal-9 might induce TIM3 overexpression in CD8 + T cells, leading to a downward trend of perforin and granzyme B after CD8 + T cells from MDS were co-cultured with MDSCs. We hypothesized that MDSCs might be a source of Gal-9. Therefore, we replaced MDSCs with excessive exogenous Gal-9 to repeat the above procedure and found that CD8 + T cells indeed produced less perforin and granzyme B after co-cultivation with excessive exogenous Gal-9, similar to that after co-cultivation with MDSCs from MDS patients. The secretion of perforin and granzyme B by CD8 + T cells could be partially restored by TIM3/Gal-9 pathway inhibitors.
Meanwhile, the early apoptosis of CD8 + T cells after co-culture with MDSCs was higher than that of CD8 + T cells alone and could be partially restored by TIM3/Gal-9 pathway inhibitors. It suggested that CD8 + T cells exhaustion might be induced by MDSC through TIM3/Gal-9 pathway.
The T-box transcription factor eomesodermin (EOMES) plays an important role in the development and maturation of CTL. 31 Notch1 could regulate perforin and granzyme B by affecting EOMES. 15, 32 Here, we found that Notch1 and EOMES decreased after co-cultivation with excessive exogenous Gal-9. It indicated that the TIM3/ and proliferation. 33 Overactivation of AKT/mTOR after phosphorylation is associated with over-proliferation of leukaemia cells, 16, 34 as well as tumour cells such as liver cancers and pancreatic neuroendocrine tumours. 35, 36 Our study found that p-mTOR and p-AKT decreased in CD8 + T cells after co-culture with exogenous Gal-9, indicating that TIM3/Gal-9 pathway might suppress CD8 + T cells through down-regulating AKT/mTOR ( Figure 6C ).
In conclusion, CD8 + T cells 'exhaustion' could be induced by up-regulating Gal-9 in MDSCs and TIM3 in CD8 + T cells of MDS patients, which was partially restored by TIM3/Gal-9 pathway inhibitors. TIM3/Gal-9 pathway may be involved in CD8 + T cells exhaustion induced by MDSCs in MDS, leading to malignant MDS clone immunological surveillance escape and over-proliferation.
Therefore, TIM3/Gal-9 pathway inhibitors might be the promising candidate for target therapy of MDS in the future. 
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